<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927431</url>
  </required_header>
  <id_info>
    <org_study_id>201023</org_study_id>
    <nct_id>NCT02927431</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza</brief_title>
  <official_title>A Phase II, Global, Randomized Study to Evaluate the Efficacy and Safety of Danirixin (GSK1325756) Co-administered With a Standard-of-care Antiviral (Oseltamivir), in the Treatment of Adults Hospitalized With Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine
      receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to
      areas of inflammation. An intravenous (IV) formulation of DNX hydrobromide (HBr) is being
      developed as an anti-inflammatory agent for treatment of adults hospitalized with influenza
      (IFV). While early therapy with antivirals decreases severity and duration of symptoms of
      influenza, there are no drugs that have demonstrated clinical efficacy in randomized clinical
      trials in this population. Current treatment guidelines for hospitalized IFV recommend
      neuraminidase inhibitors as standard of care therapy. IFV studies in animals have
      demonstrated that therapeutic treatment with the combination of a CXCR2 antagonist and a
      neuraminidase inhibitor reduced lung neutrophils and showed trends for improvements in
      clinical scores, lung function and pathology with no evidence of worsening outcomes,
      including viral load. This Phase 2, randomized, double-blind (for IV DNX), placebo-controlled
      (for IV DNX) 3-arm study will be the first study to determine the efficacy and safety of IV
      DNX when co-administered (in all groups) with standard of care antiviral treatment
      (open-label oral oseltamivir [OSV]) in subjects hospitalized with IFV. The primary objective
      of the study is to assess the efficacy of treatment with IV DNX twice daily given with oral
      OSV compared to oral OSV twice daily on time to clinical response (TTCR). In this study,
      subjects will be randomized in a 2:2:1 ratio to 15 milligram (mg) free base equivalent (FBE)
      IV DNX, 50 mg FBE IV DNX, or matching placebo twice daily. All subjects will also receive
      open-label 75 mg oral OSV, twice daily (given as standard of care). The study treatment
      duration will be for up to 5 days. The investigator may elect to continue treatment with OSV
      after 5 days of study treatment. Follow up will continue until Day 45 for all subjects. The
      study will begin with enhanced safety monitoring in sentinel cohorts, leading to stepwise
      enrollment of subjects. Subjects will be enrolled based on increasing levels of renal
      impairment, and less severe hospitalized subjects will be enrolled prior to enrollment of
      critically ill subjects, as this is the first study conducted in the hospitalized population
      with severe IFV. Approximately 300 subjects are targeted to be enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped early due to lack of enrollment.
  </why_stopped>
  <start_date type="Actual">January 19, 2017</start_date>
  <completion_date type="Actual">May 24, 2017</completion_date>
  <primary_completion_date type="Actual">May 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of time to clinical response</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Subject will be said to achieve clinical response if subject is discharged from hospital or if normalization of the following parameters are maintained for 24 hours: temperature; oxygen saturation; and 2 out of the following 3 parameters, respiratory status/heart rate/systolic blood pressure (SBP). Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to respiratory response</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Time from first dose of treatment to time of achieving respiratory response. Time to respiratory response is defined as meeting at least one of the following criteria: return to pre-morbid oxygen requirement (subjects with chronic oxygen use); or return to no requirement of supplemental oxygen; or respiratory rate &lt;=24 per minute (without supplemental oxygen). Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to absence of fever</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Time from first dose of treatment to time to afebrile status (&lt;=36.6 degree celsius-axilla or &lt;=37.2 degree celsius- oral, or &lt;=37.7 degree celsius-rectal/core, tympanic). Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improved oxygen saturation</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Time from first dose of treatment to time of improved oxygen saturation. A subject with a history of chronic hypoxia (without supplemental oxygen) will satisfy normalization criteria for oxygen saturation if the value (without supplemental oxygen) is &lt;=2% from subject's historical oxygen saturation baseline as recorded within 12 months prior to enrolment as documented in the subject's medical records. This requirement will be waived for subjects with a history of chronic supplemental oxygen requirement who have a baseline oxygen saturation &lt;95% with supplemental oxygen, within 12 months prior to enrolment as documented in the subject's medical records. Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improved heart rate</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Time from first dose of treatment to time of heart rate at &lt;=100 beats per minute. Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improved SBP</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Time from first dose of treatment to time of SBP at &gt;=90 millimeters of mercury [mmHg]. Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with clinical response over time</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Subject will be said to achieve clinical response if subject is discharged from hospital or if normalization of the following parameters are maintained for 24 hours: temperature; oxygen saturation; and 2 out of the following 3 parameters, respiratory status/heart rate/ SBP. Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improved respiratory status over time</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Time to respiratory response is defined as meeting at least one of the following criteria: return to pre-morbid oxygen requirement (subjects with chronic oxygen use); or return to no requirement of supplemental oxygen; or respiratory rate &lt;=24 per minute (without supplemental oxygen). Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of ventilation status</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Time to improvement of ventilation status will be assessed by modality, frequencies and durations of invasive and non-invasive ventilator support, duration of oxygen supplementation. Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of stay in the intensive care unit (ICU)</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Number of days of stay in the ICU over the treatment period and post treatment period will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects requiring ICU admission and readmission</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Number of subjects requiring ICU admission during treatment period and after post treatment will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of stay in the hospital</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Number of days of stay in the hospital over treatment period and post treatment period will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of development of septic shock</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Development of septic shock will be assessed by occurrence of hypotension requiring vasopressive therapy and serum lactate level &gt;2 milimeter (mM) after adequate fluid resuscitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects requiring usage of antibiotics</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Complications of influenza such as bacterial pneumonia, pneumothorax, pleural effusion, acute respiratory distress syndrome (ARDS), myositis, encephalitis, myocarditis, and associated antibiotic use will be recorded. Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 8, 15, 22, 30 and 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improvement in ordinal scale of clinical</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Number of subjects with improvement in ordinal scale of clinical efficacy over time will be assessed by: death, mechanical vent, in the ICU, non-ICU hospitalization, and hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment will be categorized as SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events of special interest (AESIs)</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Adverse events of special interest to be monitored include: pneumonias (bacterial, ventilator, hospitalized and community), pneumothorax, pleural effusion, acute respiratory distress syndrome (ARDS), myositis, encephalitis, myocarditis, bacterial bronchitis, otitis media, sepsis, sinusitis, bacteremia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum creatinine</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Baseline (Day 1), Day 5 and Day 6</time_frame>
    <description>12-lead ECGs will be obtained at each timepoint during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) for IV DNX</measure>
    <time_frame>In sentinel cohort 1 (less severe subjects with normal renal function), pharmacokinetic (PK) samples will be drawn on Day 3 at pre-dose, and 0.5, 1 (end of infusion), 1.5, 2, 3, 4, 8 and 12 hours post-dose.</time_frame>
    <description>Blood samples will be collected to evaluate AUC as a measure of pharmacokinetics of IV DNX in subjects hospitalized for influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed drug concentration (Cmax) for IV DNX</measure>
    <time_frame>In sentinel cohort 1 (less severe subjects with normal renal function), pharmacokinetic (PK) samples will be drawn on Day 3 at pre-dose, and 0.5, 1 (end of infusion), 1.5, 2, 3, 4, 8 and 12 hours post-dose.</time_frame>
    <description>Blood samples will be collected to evaluate Cmax as a measure of pharmacokinetics of IV DNX in subjects hospitalized for influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration (Cavg) for IV DNX</measure>
    <time_frame>Pre-dose samples will be drawn on Day 1 (before second dose), Day 3 and Day 5. In sentinel cohort 1, additional PK samples will be drawn on Day 3 at PD, and 0.5, 1 (end of infusion), 1.5, 2, 3, 4, 8 and 12 hours post-dose.</time_frame>
    <description>Blood samples will be collected to characterize Cavg of IV DNX in subjects hospitalized for influenza.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood urea nitrogen (BUN)</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in potassium</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in aspartate transaminase (AST)</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total and direct bilirubin</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sodium</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in alanine transaminase (ALT)</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total protein</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in calcium</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in alkaline phosphatase</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in albumin</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in red blood cell count (RBC)</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hematocrit</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean corpuscular volume (MCV)</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean corpuscular hemoglobin (MCH)</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in differential white blood cell count (WBC)</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in platelet count</measure>
    <time_frame>Baseline and up to 45 Days</time_frame>
    <description>Subjects will be assessed daily during treatment and post treatment inpatient days up to discharge or Day 45. For subjects who are discharged before Day 45, outpatient assessments will also be done on post treatment Day 3 and study Day 45.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>Danirixin 15 mg FBE IV plus 75 mg oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Danirixin 50 mg FBE IV plus 75 mg oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of danirixin IV plus 75 mg oseltamivir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danirixin 15 mg FBE</intervention_name>
    <description>This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.</description>
    <arm_group_label>Danirixin 15 mg FBE IV plus 75 mg oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danirixin 50 mg FBE</intervention_name>
    <description>This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.</description>
    <arm_group_label>Danirixin 50 mg FBE IV plus 75 mg oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.</description>
    <arm_group_label>Placebo of danirixin IV plus 75 mg oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir 75 mg</intervention_name>
    <description>Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.</description>
    <arm_group_label>Danirixin 50 mg FBE IV plus 75 mg oseltamivir</arm_group_label>
    <arm_group_label>Placebo of danirixin IV plus 75 mg oseltamivir</arm_group_label>
    <arm_group_label>Danirixin 15 mg FBE IV plus 75 mg oseltamivir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years (as per local laws) of age and older at the time of signing the
             informed consent.

          -  Presence of fever (&gt;=38.0 degree Celsius [&gt;=100.4 degree Fahrenheit] by any route) at
             Baseline (enrollment) or history of fever/feverishness during the 48 hours prior.

          -  Oxygen (O2) saturation &lt;95% on room air by trans-cutaneous method OR need for any
             supplemental oxygenation (non-invasive ventilation, facemask, facetent, nasal canula,
             etc) or ventilator support (mechanical ventilation, bi-level positive airway pressure
             [BIPAP], continuous positive airway pressure [CPAP]) or increase in oxygen
             supplementation requirement of &gt;=2 liters for subjects with chronic oxygen dependency.
             For those subjects with a history of chronic hypoxia (without supplemental oxygen), an
             oxygen saturation of at least 3% below the subject's historical baseline oxygen
             saturation.

          -  And at least 2 out of the following 3: respiratory rate &gt;24 breaths per minute. For
             those subjects who require ventilator support or oxygen supplementation, this
             requirement is waived; heart rate &gt;100 beats per minute; SBP &lt;90 millimeters of
             mercury (mm Hg).

          -  Severity of symptoms at enrollment: 1) Less severe hospitalized subjects are those who
             (but not limited to): are hemodynamically stable; may require oxygenation with
             facemask, facetent, nasal canula, etc; may or may not have radiological signs of lower
             respiratory tract disease; or have exacerbation of underlying chronic disease,
             including asthma, chronic obstructive pulmonary disease (COPD), or other
             cardiovascular conditions not leading to hemodynamic compromise. 2) Critically ill
             hospitalized subjects are those who (but not limited to): require CPAP, BIPAP,
             mechanical ventilation; have hemodynamic instability (with or without pressor
             support); or have central nervous system involvement (example encephalopathy,
             encephalitis).

          -  Presence of influenza that in the Investigator's judgment requires hospitalization for
             treatment and supportive care

          -  Onset of influenza symptoms within 6 days prior to study enrolment. Symptoms may
             include cough, dyspnea, sore throat, feverishness, myalgias, headache, nasal symptoms
             (rhinorrhea, congestion), fatigue, diarrhea, nausea and vomiting.

          -  A positive result from a rapid influenza test (provided by GlaxoSmithKline [GSK]) or
             other available, local laboratory diagnostic test

          -  Baseline renal criteria as follows: 1) Sentinel Cohorts: Normal renal function:
             Baseline creatinine clearance within normal reference ranges (&gt;=80 milliliter per
             minute (mL/min) for the first approximately 30 subjects enrolled; Mild renal
             impairment: Baseline creatinine clearance of 50-79 mL/min for the next approximately
             10 subjects enrolled into the sentinel cohort; Moderate renal impairment: Baseline
             creatinine clearance of 30-49 mL/min for the next approximately 10 subjects enrolled
             into the sentinel cohort. 2) Post-sentinel cohorts: Normal renal function, mild or
             moderate renal impairment: creatinine clearance &gt;30mL/min.

          -  Baseline Liver Function Tests: Subjects will be included if:

               1. ALT is &lt;=5 times the upper limit of normal (ULN) and bilirubin is &lt;=2 times the
                  ULN

               2. ALT is &gt;5 but &lt;=8 times the ULN and bilirubin is &lt; 1.5 times the ULN

          -  Male or Female subjects could be eligible if: Male subjects with female partners of
             child bearing potential must comply with the pre-specified highly effective
             contraception requirements from the time of first dose of study medication until at
             least 36 hours (five half-lives) after the last dose of study medication. 1) Vasectomy
             with documentation of azoospermia 2) Male condom plus partner use of one of the
             contraceptive options below: Contraceptive subdermal implant; Intrauterine device or
             intrauterine system; Oral Contraceptive, either combined or progestogen alone;
             Injectable progestogen; Contraceptive vaginal ring; Percutaneous contraceptive patches

          -  For females, non-reproductive potential defined as: 1) Pre-menopausal females with one
             of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion
             procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy;
             Documented Bilateral Oophorectomy 2) Postmenopausal defined as 12 months of
             spontaneous amenorrhea [in questionable cases a blood sample with simultaneous
             follicle stimulating hormone (FSH) and estradiol levels consistent with menopause
             (refer to laboratory reference ranges for confirmatory levels)]. Females on hormone
             replacement therapy (HRT) and whose menopausal status is in doubt will be required to
             use one of the highly effective contraception methods if they wish to continue their
             HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of
             post-menopausal status prior to study enrolment. 3) Reproductive potential and agrees
             to follow one of the options listed in the Modified List of Highly Effective Methods
             for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from the first dose
             of study medication until at least 36 hours after the last dose of study medication
             and completion of the post treatment (PT) Day 3 visit. The investigator is responsible
             for ensuring that subjects understand how to properly use these methods of
             contraception.

          -  Subjects willing and able to give written informed consent to participate in the study
             and to adhere to the procedures stated in the protocol OR Legally acceptable
             representative (LAR) willing and able to give written informed consent on behalf of
             the subject to participate in the study for unconscious adults, and those incapable of
             consenting themselves due to their medical condition (e.g. too weak or debilitated,
             severe shortness of breath), due to literacy issues or included as permitted by local
             regulatory authorities, institutional review board (IRB)/independent ethics committee
             (IECs) or local laws.

          -  French subjects: In France, a subject will be eligible for inclusion in this study
             only if either affiliated to or a beneficiary of a social security category.

        Exclusion Criteria:

          -  Subjects who, in the opinion of the investigator, are not likely to survive the next
             48 hours beyond Baseline;

          -  Immunosuppression, whether due to primary immunosuppressive conditions, such as
             history of inherited immunodeficiency syndromes, human immunodeficiency virus (HIV)
             infection, or secondary conditions, such as immunosuppressive medication, stem cell or
             solid organ transplantation, or malignancy;

          -  Documented current liver disease (including Hepatitis A, B, or C), or known hepatic or
             biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic
             gallstones);

          -  Baseline Liver Function Tests: Subjects will be excluded if:

               1. ALT &gt;8 times the ULN

               2. Bilirubin is &gt;2 times the ULN

          -  Corrected QT Interval (QTc) Criteria: Corrected QT Interval using Bazette's formula
             (QTcB) or Corrected QT Interval using Fridericia forumula (QTcF) &gt;480 millisecond
             (msec) or &gt;500 msec with bundle branch block;

          -  For subjects enrolled in the sentinel cohorts: diabetes mellitus and chronic kidney
             disease;

          -  Subjects who require dialysis, or are on renal replacement therapies;

          -  Subjects who require extra corporeal membrane oxygenation (ECMO) at baseline (enrolled
             subjects who subsequently require ECMO may continue in the study)

          -  Women who are pregnant as determined by a positive human chorionic gonadotrophin (hCG)
             ultrasensitive test prior to dosing or women who are breastfeeding;

          -  Subjects who received other treatments for influenza including vitaglutam, umifenovir,
             and neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) for more than 72
             hours during current acute illness;

          -  Subjects who received any immunoglobulins within 6 months of screening or planned
             administration of any of these products during the treatment period.

          -  Subjects treated with cytotoxic or immunosuppressive drugs within six months of study
             enrolment. Topical, intra-articularly injected, or inhaled glucocorticoids, topical
             calcineurin inhibitors or imiquimod are allowed.

          -  Known history of drug abuse within 6 months of study start.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or Medical
             Monitor, contraindicates their participation.

          -  Absolute neutrophil count &lt;1.0 giga per Liter (Gi/L)

          -  Subjects who have participated in a clinical trial using an investigational product
             within the following time period prior to the first dosing day in the current study:
             30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Natchitoches</city>
        <state>Louisiana</state>
        <zip>71457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Mans cedex 09</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orl√©ans cedex 2</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Strasbourg cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours cedex 9</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gangwon-do</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suceava</city>
        <zip>720284</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chita</city>
        <zip>672038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alcorcon</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huelva</city>
        <zip>21080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-inflammatory</keyword>
  <keyword>Danirixin</keyword>
  <keyword>Influenza</keyword>
  <keyword>Hospitalized patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 20, 2018</submitted>
    <returned>May 18, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

